Premium
P1‐092: PBD‐C06 – A NOVEL ANTI‐PGLU3‐Aβ ANTIBODY FOR IMMUNOTHERAPY AGAINST ALZHEIMER'S DISEASE
Author(s) -
Rahfeld Jens-Ulrich,
Kleinschmidt Martin,
Gillies Stephen D.,
Makioka Kouki,
Lemere Cynthia A.,
Schilling Stephan,
Hettmann Thore
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.647
Subject(s) - antibody , chemistry , epitope , antibody dependent cell mediated cytotoxicity , biochemistry , in vitro , microbiology and biotechnology , biophysics , biology , cytotoxicity , immunology
compounds Y12d, Y12e, Y12f and Y12j possessed preferably good docking score showing the interaction with both PAS and CAS of AChE. All the compounds of Y13 except Y13a and Y13b exhibit good docking score (-8.3 to -10.6) and shows interaction with HIS440 through p-p interaction and with ASP72, PHE331 and TYR334 through H-bonding. Conclusions: The study reveals the importance of chain length combining the two moieties i.e., chain length of 2-3 atoms is most appropriate for good affinity towards AChE.